Contribution: Industrial Research Assistance Program – Contributions to Firms
9397-2677 Québec inc.
$99,500.00
Ex vivo use of mouse tumor microdissections for preclinical development of cancer immunotherapies
FY 2021-22 · 2021-09-15
Summary
The project aims to establish the utility of the technology to test, in a single ex vivo experiment, several combinations of immunotherapies to identify the most effective one, and to screen murine tumor models to identify the best preclinical model to study a given immunotherapy.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montréal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
773986138
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-09-15 | 2021-22 | $99,500.00 |
| 2 | 2021-09-15 | 2021-22 | $99,500.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 75 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 75 jours.
Agreement End Date
2022-11-30
Agreement Number
979207
Agreement Start Date
2021-09-15
Agreement Title
Ex vivo use of mouse tumor microdissections for preclinical development of cancer immunotherapies
Agreement Title (French)
Utilisation ex vivo de microdissections de tumeurs de souris pour le développement préclinique d'immunothérapies en cancérologie
Agreement Type
Contribution
Agreement Value
$99,500.00
Amendment Date
2022-08-30
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The project aims to establish the utility of the technology to test, in a single ex vivo experiment, several combinations of immunotherapies to identify the most effective one, and to screen murine tumor models to identify the best preclinical model to study a given immunotherapy.
Description (French)
Le projet vise à établir l'utilité de la technologie pour tester, dans une seule expérience ex vivo, plusieurs combinaisons d’immunothérapies, pour identifier la plus efficace, et à cribler des modèles de tumeurs murines afin d'identifier le meilleur modèle préclinique pour étudier une immunothérapie donnée.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Papineau
Federal Riding (French)
Papineau
Federal Riding Number
24055
NAICS Code
54171
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
773986138
Recipient City
Montreal|Montréal
Recipient Country
CA
Recipient Legal Name
9397-2677 Québec inc.
Recipient Operating Name
MisoChip
Recipient Postal Code
H2R 2P2
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q3-979207
